Roy Koruth

Roy Koruth is an accomplished professional in the pharmaceutical industry with extensive experience in market access and portfolio strategy. Currently serving as Portfolio Strategy Lead for Patient Access and Quality in US Medical Affairs at Gilead Sciences, Roy is responsible for developing US Evidence Strategy for the oncology and virology portfolios. Previously, as the Global Value & Access Head for Liver and Inflammation at Gilead, Roy managed teams focused on Hepatitis B, C, and Delta. Prior roles at Novartis included Global Access Product Lead for Taf/Mek in melanoma and US Market Access Director for the cardiovascular portfolio. Roy began his career at PriceSpective and Bridgehead International Ltd, focusing on pricing research and health technology assessment. Roy holds a BA (Hons) in Biochemistry from Hertford College, Oxford University, and two MSc degrees in Technical Change and Industrial Strategy from The University of Manchester.